Group items matching

in title, tags, annotations or url

Is the MP Treatment for Sarcoidosis Helpful for Other Chronic Diseases? MP's Vitamin D Theories Are Not Supported by Lab Studies. Updated July 2, 2008 "The MP treatment plan was originally designed to treat an inflammatory condition known as sarcoidosis. The treatment consists of using the drug Benicar, combined with the avoidance of all sources of vitamin D, and eventually adding various antibiotics, especially minocycline. After being used by sarcoidosis patients for some years, it was then theorized and claimed that the treatment could treat other inflammatory conditions. Eventually it was also claimed that it could treat fibromyalgia and CFS, conditions which are not recognized by the medical literature as being inflammatory in nature. "

Vitamin D and prevention of breast cancer: pooled analysis. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, Newmark H, Holick MF, Garland FC. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):708-11. PMID: 17368188 CONCLUSIONS: Intake of 2000 IU/day of Vitamin D(3), and, when possible, very moderate exposure to sunlight, could raise serum 25(OH)D to 52 ng/ml, a level associated with reduction by 50% in incidence of breast cancer, according to observational studies.

Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Breast Cancer Res Treat. 2009 Oct 23. [Epub ahead of print] PMID: 19851861 These results provide strong evidence that vitamin D and calcium have a chemopreventive effect against breast cancer.

Nutritional vitamin D status during pregnancy: reasons for concern. Hollis BW, Wagner CL. CMAJ. 2006 Apr 25;174(9):1287-90. PMID: 16636329 doi:10.1503/cmaj.060149.

The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Gombart AF. Future Microbiol. 2009 Nov;4:1151-65. PMID: 19895218 doi:10.2217/fmb.09.87

A vitamin D nutritional cornucopia: new insights concerning the serum 25-hydroxyvitamin D status of the US population. Norman AW. Am J Clin Nutr. 2008 Dec;88(6):1455-6. PMID: 19064502 doi:10.3945/ajcn.2008.27049 In summary, the report of Looker et al should be required reading for all nutritionists, clinicians, and vitamin D aficionados who are decision makers with regard to 25(OH)D assays, vitamin D nutritional policy, and the care of patients with vitamin D-related diseases.